A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic ScreeningMichael L. Beshiri, Kathleen Kelly, Caitlin M. Tice et al.|Clinical Cancer Research|2018Cited by 236
High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancerKeith H. Jansson, Kathleen Kelly, Shelley Hoover et al.|Scientific Reports|2018Cited by 33
Stem cell dynamics and cellular heterogeneity across lineage subtypes of castrate-resistant prostate cancerMichael L. Beshiri, Kathleen Kelly, Brian J. Capaldo et al.|Stem Cells|2024Cited by 6
The origin and dynamics of cellular heterogeneity vary across lineage subtypes of castrate resistant prostate cancerMichael L. Beshiri, Kathleen Kelly, Brian J. Capaldo et al.|bioRxiv (Cold Spring Harbor Laboratory)|2022Cited by 3
Supplementary Materials from A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic ScreeningMichael L. Beshiri, Kathleen Kelly, Caitlin M. Tice et al.|Unknown|2023Cited by 0